Studies on obese diabetic (ob/ob) mice showed that GIP (Lys16PAL) and GIP (Lys37PAL) long-acting analogs for GIPR increased the insulin response to glucose and improved glucose tolerance [58]
Simultaneously, GLP-1 receptor activation stimulates glucose-dependent insulin release from pancreatic beta cells, suppresses inappropriate glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system pathways
If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting GLP-1 treatment or any new prescription medication
Currently in late-stage clinical trials with FDA response expected in 2026
Levin Papantonio Rafferty (LPR) Attorney Cameron Stephenson was appointed to the Plaintiffs Executive Committee in this MDL